Centre Bans 16 Drug Combinations Across India to Protect Public Health

New Delhi: In a major move aimed at protecting public health, the Union Ministry of Health and Family Welfare has banned the manufacture, sale, and distribution of 16 Fixed Dose Combinations (FDCs) across India with immediate effect. The decision comes after a scientific review found that these drug combinations lacked proper therapeutic justification and could pose risks to patients.

What Are Fixed Dose Combinations?

Fixed Dose Combinations (FDCs) are medicines that combine two or more active ingredients into a single product. While many FDCs offer benefits and convenience, health experts say some combinations may not provide additional medical advantages and could increase health risks.

Why Did the Government Ban Them?

The action follows directions from the Supreme Court, which ordered a detailed review of various FDCs available in the country.

Following the court’s directions, the Drugs Technical Advisory Board (DTAB) formed an Expert Committee to examine the safety, effectiveness, and medical value of several drug combinations.

After reviewing the available scientific evidence, the committee found that 16 FDCs lacked therapeutic justification. The committee also concluded that the potential risks outweighed the benefits of these medicines.

Based on these findings, the Health Ministry invoked Section 26A of the Drugs and Cosmetics Act, 1940, to prohibit the products.

Types of Medicines Affected

The banned combinations belong to different categories of medicines, including:

  • Pain relief medicines
  • Antispasmodic drugs
  • Dermatological products
  • Antibiotic-based formulations
  • Diabetes-related medicines

Some of the prohibited combinations include:

  • Acetyl Salicylic Acid + Ethoheptazine
  • Dicyclomine + Paracetamol + Clidinium Bromide
  • Gliclazide + Chromium Picolinate
  • Paracetamol + Lignocaine
  • Amoxicillin + Serratiopeptidase
  • Cefuroxime + Serratiopeptidase
  • Cefadroxyl + Probenecid

Immediate Nationwide Ban

The ministry has directed all State Drug Controllers, regulatory authorities, and enforcement agencies to ensure strict implementation of the ban. Manufacturers, distributors, importers, and retailers have also been instructed to stop the manufacture, sale, distribution, and supply of the identified products immediately.

Focus on Safe and Effective Medicines

The Health Ministry said the move reflects the government’s commitment to ensuring that only safe, effective, and scientifically validated medicines remain available to the public.

The ministry has previously banned several irrational drug combinations after expert reviews. Officials say these steps help improve patient safety and promote evidence-based healthcare practices.

With the latest notification now in force, the 16 prohibited Fixed Dose Combinations can no longer be manufactured, sold, or distributed anywhere in India.

Related Posts

Delhi-Varanasi Bullet Train Corridor Moves Ahead With DPR Submission

The 865-km Delhi-Varanasi-Patna-Siliguri bullet train corridor has moved ahead after NHSRCL submitted the Detailed Project Report.

UPI Charges From October 15: New MDR Rules for Some Merchant Payments

New UPI MDR rules will apply to certain merchant payments above ₹2,000 from October 15, 2026, with exemptions for eligible small merchants.

Rajasthan Eklavya Schools to Get Smart Classrooms and Computer Labs

Eklavya Model Residential Schools in Rajasthan will get computer labs and smart classrooms through a ₹16 crore-plus CSR project.

CCPA Fines Rapido ₹10 Lakh for Misleading Tipping Prompts

CCPA has imposed a ₹10 lakh penalty on Rapido over misleading tipping prompts and the use of a Confirm Shaming dark pattern

UPI Merchant Fees 2026: New Charges for Some Payments

New UPI merchant fees will apply to some payments above ₹2,000 from October 15, 2026, while P2P transfers remain free.